{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010526","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.046565+00:00","generated_at":"2026-05-21T05:10:21.615567+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evofem Q1 net income $1.0M, revenue $0.8M; plans 55-60% PHEXXI COGS cut","bullets":["Net sales $0.8M, down 78% from $3.6M YoY due to order timing after Q4 2024 stocking.","Net income $1.0M ($0.01 basic EPS) vs net loss $4.9M ($0.16 loss) in Q1 2024.","Partnered with Windtree to reduce PHEXXI manufacturing cost by 55-60%; Evofem bears no tech transfer costs.","Received $1.5M in April from sale of notes/warrants to Aditxt under merger agreement.","Cash and restricted cash $1.1M at March 31, 2025; new U.S. patent for SOLOSEC extends to 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010526","json":"https://secwatch.observer/filing/0001641172-25-010526.json","markdown":"https://secwatch.observer/filing/0001641172-25-010526.md","text":"https://secwatch.observer/filing/0001641172-25-010526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/0001641172-25-010526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:10:21.615567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}